OBJECTIVE: Human papilloma virus (HPV) positive and HPV negative head and neck squamous cell cancer (HNSCC) are biologically distinct with a prognostic advantage for HPV positive patients compared to HPV negative cases. DNA promoter methylation is central to human diseases such as cancer, including HNSCC, with reported genome-wide hypomethylaton and promoter hypermethylation in HPV positive HNSCC tumors. The goal of this study was to identify differentially methylated genes in HPV positive versus HPV negative primary HNSCC genomes with clues to signaling networks. STUDY DESIGN: Laboratory-based study. SETTING: Primary care academic health care system. SUBJECTS AND METHODS: DNA from 4 HPV positive and 4 HPV negative freshly frozen primary HNSCC were subject to comprehensive genome-wide methylation profiling. Differentially methylated gene lists were examined using the Signal Transduction Pathways (canonical) filter in the Genomatix Pathway System (GePS). RESULTS: Twofold methylation differences were observed between HPV positive and HPV negative cases for 1168 genes. Pathway analysis applied to investigate the biological role of the 1168 differentially methylated genes revealed 8 signal transduction pathways forming a network of 66 genes, of which 62% are hypermethylated. CONCLUSION: Our study reveals a predominant hypermethylation profile for genes in signal transduction pathways of HPV positive HNSCC tumor genomes. Because signaling events in the cell play a critical role in the execution of key biological functions, insights into how complex cellular signaling cascades and networks may be programmed in HNSCC are likely to be critical in the development of new biological agents designed to hit multiple targets.
OBJECTIVE:Human papilloma virus (HPV) positive and HPV negative head and neck squamous cell cancer (HNSCC) are biologically distinct with a prognostic advantage for HPV positive patients compared to HPV negative cases. DNA promoter methylation is central to human diseases such as cancer, including HNSCC, with reported genome-wide hypomethylaton and promoter hypermethylation in HPV positive HNSCC tumors. The goal of this study was to identify differentially methylated genes in HPV positive versus HPV negative primary HNSCC genomes with clues to signaling networks. STUDY DESIGN: Laboratory-based study. SETTING: Primary care academic health care system. SUBJECTS AND METHODS: DNA from 4 HPV positive and 4 HPV negative freshly frozen primary HNSCC were subject to comprehensive genome-wide methylation profiling. Differentially methylated gene lists were examined using the Signal Transduction Pathways (canonical) filter in the Genomatix Pathway System (GePS). RESULTS: Twofold methylation differences were observed between HPV positive and HPV negative cases for 1168 genes. Pathway analysis applied to investigate the biological role of the 1168 differentially methylated genes revealed 8 signal transduction pathways forming a network of 66 genes, of which 62% are hypermethylated. CONCLUSION: Our study reveals a predominant hypermethylation profile for genes in signal transduction pathways of HPV positive HNSCC tumor genomes. Because signaling events in the cell play a critical role in the execution of key biological functions, insights into how complex cellular signaling cascades and networks may be programmed in HNSCC are likely to be critical in the development of new biological agents designed to hit multiple targets.
Entities:
Keywords:
gene networks; hypermethylation; pathways; signal transduction
Authors: Peter S Gargalovic; Minori Imura; Bin Zhang; Nima M Gharavi; Michael J Clark; Joanne Pagnon; Wen-Pin Yang; Aiqing He; Amy Truong; Shilpa Patel; Stanley F Nelson; Steve Horvath; Judith A Berliner; Todd G Kirchgessner; Aldons J Lusis Journal: Proc Natl Acad Sci U S A Date: 2006-08-15 Impact factor: 11.205
Authors: Maria J Worsham; Josena K Stephen; Kang Mei Chen; Meredith Mahan; Vanessa Schweitzer; Shaleta Havard; George Divine Journal: Clin Cancer Res Date: 2013-03-26 Impact factor: 12.531
Authors: Liselotte Dahlgren; Hanna Mellin; Danny Wangsa; Kerstin Heselmeyer-Haddad; Linda Björnestål; Johan Lindholm; Eva Munck-Wikland; Gert Auer; Thomas Ried; Tina Dalianis Journal: Int J Cancer Date: 2003-11-01 Impact factor: 7.396
Authors: Maria J Worsham; Kang Mei Chen; Indrani Datta; Josena K Stephen; Dhananjay Chitale; Alexandra Gothard; George Divine Journal: Oncol Lett Date: 2016-10-21 Impact factor: 2.967
Authors: Maarouf A Saad; Jonjei Ku; Selena Z Kuo; Pin Xue Li; Hao Zheng; Michael Andrew Yu; Jessica Wang-Rodriguez; Weg M Ongkeko Journal: Oncol Lett Date: 2019-01-09 Impact factor: 2.967
Authors: Steven F Gameiro; Farhad Ghasemi; John W Barrett; Anthony C Nichols; Joe S Mymryk Journal: Cancers (Basel) Date: 2019-08-07 Impact factor: 6.639
Authors: Daria A Gaykalova; Rajita Vatapalli; Yingying Wei; Hua-Ling Tsai; Hao Wang; Chi Zhang; Patrick T Hennessey; Theresa Guo; Marietta Tan; Ryan Li; Julie Ahn; Zubair Khan; William H Westra; Justin A Bishop; David Zaboli; Wayne M Koch; Tanbir Khan; Michael F Ochs; Joseph A Califano Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240
Authors: Ali Khammanivong; Brent S Sorenson; Karen F Ross; Erin B Dickerson; Rifat Hasina; Mark W Lingen; Mark C Herzberg Journal: Oncotarget Date: 2016-03-22